

Date of the CVA

28/01/2019

## Section A. PERSONAL DATA

Name and Surname	Enrique de Álava Casado		
DNI	18203958X	Age	54
Researcher's identification number	Researcher ID		
	Scopus Author ID		
	ORCID	0000-0001-8400-046X	

### A.1. Current professional situation

Institution	Universidad de Sevilla y Hospital Universitario Virgen del Rocío		
Dpt. / Centre			
Address	Dept. of Pathology, Virgen del Rocío University Hospital/IBiS, 41013, Sevilla		
Phone	(+34) 671596572	Email	<a href="mailto:enrique.alava.sspa@juntadeandalucia.es">enrique.alava.sspa@juntadeandalucia.es</a>
Professional category	Profesor titular de Universidad Vinculado	Start date	2016
UNESCO spec. code	320700 - pathology		
Keywords			

### A.2. Academic education (Degrees, institutions, dates)

Bachelor/Master/PhD	University	Year

### A.3. General quality indicators of scientific production

## Section B. SUMMARY OF THE CURRICULUM

Enrique de Álava M.D., PhD. (Pamplona, Spain, 1964) is, since 2013, the Chairman, Department of Pathology at the University Hospital Virgen del Rocío, Principal Investigator at the Seville Institute of Biomedicine, and scientific coordinator of the Campus Biobank, all in Seville, Spain. He is a Pathologist with special interest in Bone and soft tissue Pathology, in Diagnostic Molecular Pathology, with a particular focus on sarcoma translational research. He chaired the Spanish Society of Pathology, the Spanish Division of the International Academy of Pathology between May 2015 and May 2017. He is a Vice-President for Europe of the International Academy of Pathology (IAP).

Enrique de Álava obtained a degree in Medicine and Surgery at the University of Navarra in 1988, finishing his training as a specialist in Pathology in 1993 at the University Clinic of Navarra. He got a PhD in Medicine and Surgery from the University of Navarra (1993). He completed his postdoctoral training in the Department of Pathology at Memorial Sloan Kettering Cancer Center in New York, in the laboratory of William Gerald, from 1994 to 1996, thanks to a postdoctoral fellowship from the Spanish Ministry of Education and Science.

Enrique de Álava became a tenured research scientist of the Spanish Research Council (CSIC) in 2003, and became a Principal Investigator of the Laboratory of Molecular Pathology at the Cancer Research Center of Salamanca, Spain, coordinator of the Regional Biobank of Castilla and León, and Deputy Director of the National DNA Biobank. In 2009 he was promoted to CSIC Full Research Professor. In July 2010 he joined the Department of Pathology, University Hospital of Salamanca, as an Attending Pathologist.

His main research focus is translational research of sarcomas. His research objectives are the search and validation of new therapeutic targets, mechanisms of sarcomagenesis and validation of new tools directly applicable to the hospital diagnostic routine. He has obtained in the last 10 years competitive funding from the European Commission (FP6 and FP7 through

the Network of Excellence EuroBoNet, the Eurosarc project, the PROVABES project and Euroewing-EEC project), the Institute of Health Carlos III, MINECO-RETOS, and the Scientific Foundation of the AECC (Spanish Association Against Cancer). He has also got private funds from six different charities, PharmaMar, Pfizer, Astra-Zeneca, Roche, and Dako-Agilent. He is also leading (2013-2018) a consortium that has a stable cooperative project funded by the AECC on Ewing sarcoma .

He is strongly committed to dissemination of cancer research to patients, patient organisations, and High School students. During the last 5 years he has participated in over 20 dissemination activities, some of them in AECC-organised meetings, some of them through 'La semana de la ciencia'. He is very active in social media networks under @EnriqueDeAlava.

He belongs to the National Technical Committee of the Spanish Association Against Cancer (AECC) (2017-).

He is a coordinator of the Cancer Evaluation panel at the National Agency for Evaluation and Prospective, National Research Agency-MINECO (2018-)

He has got recognized 4 periods of research activity by the Spanish CNEAI ("sexenios" 1990-2013)

He is the director of 8 doctoral theses. His H index is 42.

## Section C. MOST RELEVANT MERITS (ordered by typology)

### C.1. Publications

- 1 **Scientific paper.** J Díaz-Martín; et al. (6/6). 2018. What's in a name? Molecular sub-classification of sarcomas creates fresh challenges Journal of Pathology.
- 2 **Scientific paper.** Puerto-Camacho P; et al. (26/26). 2018. Preclinical efficacy of endoglin-targeting antibody-drug conjugates for the treatment of Ewing sarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research. ISSN 1078-0432.
- 3 **Scientific paper.** Casali PG; et al. (74/14). 2018. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.Annals of oncology : official journal of the European Society for Medical Oncology. 29, pp.iv79-iv95. ISSN 0923-7534.
- 4 **Scientific paper.** TGP Grunewald; et al. (9/5). 2018. Ewing sarcoma Nature Reviews Disease Primers. 5-1, pp.5-26.
- 5 **Scientific paper.** Sheffield NC; et al. (38/19). 2017. DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma.Nature Medicine.
- 6 **Scientific paper.** JL Ordóñez; et al. (18/18). 2015. The PARP inhibitor olaparib enhances the sensitivity of ewing sarcoma to trabectedin.Oncotarget.
- 7 **Scientific paper.** K Scotlandi; et al. (15/14). 2015. Trabectedin Efficacy in Ewing Sarcoma Is Greatly Increased by Combination with Anti-IGF Signaling Agents.Clin Cancer Res. 21-6, pp.1373-1382. ISSN 1078-0432.
- 8 **Scientific paper.** Mackintosh C; et al. (7/7). 2013. WEE1 accumulation and deregulation of S-phase proteins mediate MLN4924 potent inhibitory effect on Ewing sarcoma cells ONCOGENE. 32-11, pp.1441-1451.
- 9 **Scientific paper.** Martin-Broto J.; et al. (28/6). 2019. Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial The Lancet. Oncology. 20, pp.134-144.
- 10 **Scientific paper.** DJ García-Domínguez; et al. (11/11). 2018. The combination of epigenetic drugs SAHA and HCI-2509 synergistically inhibits EWS-FLI1 and tumor growth in Ewing sarcoma.Oncotarget. 9-59, pp.31397-31410.
- 11 **Scientific paper.** MC Baldauf; et al. (9/6). 2018. Are EWSR1-NFATc2-positive sarcomas really Ewing sarcomas? Modern Pathology. 31-6, pp.997-999. ISSN 1530-0285.

- 12 Scientific paper.** Casali, PG.; et al. 2018. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of oncology : official journal of the European Society for Medical Oncology*. ISSN 1569-8041.
- 13 Scientific paper.** Casali, PG.; et al. 2018. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of oncology : official journal of the European Society for Medical Oncology*. ISSN 1569-8041.
- 14 Scientific paper.** S García-Monclus; et al. (13/10). 2018. EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma. *Int J Cancer*. ISSN 1097-0215.
- 15 Scientific paper.** Eduardo Alcaraz Mateos; et al. 2018. Pathology in social media networks. Recruitment campaign *Revista Española de Patología*. 51, pp.6-13.
- 16 Scientific paper.** Hontecillas Prieto, L.; et al. (6/6). 2017. HMGA2 overexpression predicts relapse susceptibility of blastemal Wilms tumor patients. *Oncotarget*. 8-70, pp.115290-115303. ISSN 1949-2553.
- 17 Scientific paper.** Mora J; et al. 2017. GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS) *British Journal of Cancer*. 117-6, pp.767-774.
- 18 Scientific paper.** Garrido P, Aldaz A, Vera R, Calleja MA, de Álava E, Martín M, Matías-Guiu X, Palacios J. 2017. Proposal for the creation of a national strategy for precision medicine in cancer: a position statement of SEOM, SEAP, and SEFH. *Clin Transl Oncol*. 2017.
- 19 Scientific paper.** MC Baldauf; et al. 2017. Robust diagnosis of Ewing sarcoma by immunohistochemical detection of super-enhancer-driven EWSR1-ETS targets *Oncotarget*. 9, pp.1587-1601.
- 20 Scientific paper.** 1; et al. (7/7). 2017. Multidrug resistance transporter profile reveals MDR3 as a marker for stratification of blastemal Wilms tumour patients *Oncotarget*. e-pub ahead of print.
- 21 Scientific paper.** I Hernandez-Muñoz; et al. (16/15). 2016. RING1B contributes to Ewing sarcoma development by repressing the Nav1.6 sodium channel and the NF-κB pathway, independently of the fusion oncoprotein *Oncotarget*.

## C.2. Participation in R&D and Innovation projects

- 1** PE-0186-2018, Caracterización molecular de fusiones génicas en el sarcoma del estroma endometrial: Hacia una medicina de precisión. Consejería de Salud de la Junta de Andalucía. Convocatoria de proyectos estratégicos de I+D+i. ENRIQUE DE ALAVA CASADO. (INSTITUTO DE BIOMEDICINA DE SEVILLA). 01/01/2019-31/12/2022. 197.390 €. Principal investigator.
- 2** RTC-2017-6573-1, CULTIVOS 3D PERSONALIZADOS PARA SELECCIÓN DE TRATAMIENTO PARA PACIENTES DE CÁNCER EN MEDICINA DE PRECISIÓN (PROYECTO 3D-ID). Ministerio de Ciencia e Innovación. Universidades. RETOS COLABORACIÓN. ANGEL GARCÍA MARTÍN. (INSTITUTO DE BIOMEDICINA DE SEVILLA). 01/01/2019-31/12/2021. 164.890 €. Co-ordinator.
- 3** Nuevas dianas terapéuticas en el sarcoma de Ewing a través del estudio del proceso metastásico Enrique de Alava. (INSTITUTO DE BIOMEDICINA DE SEVILLA). 01/01/2018-31/12/2020. 135.520 €.
- 4** FP7-HEALTH.2013.2.4.1-1, Project ID: 602856, EURO EWING Consortium – International Clinical Trials to Improve Survival from Ewing Sarcoma (ECC) Comisión Europea. Enrique de Alava Casado. (INSTITUTO DE BIOMEDICINA DE SEVILLA). 01/12/2013-31/12/2018. 200.000 €.
- 5** HEALTH.2011.2.4.1-1 - Investigator-driven treatment trials for rare cancers, European Clinical trials in Rare Sarcomas within an integrated translational trial network (EUROSARC) Comisión Europea FP7. Enrique de Alava Casado. (INSTITUTO DE BIOMEDICINA DE SEVILLA). 01/01/2012-21/12/2018. 300.000 €. Co-ordinator.

- 6 GCB13131578DE Á, Search, validation, and clinical translation of new therapeutic targets in Ewing sarcoma terapéuticas after integrative genomics and epigenomics in Ewing sarcoma ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER- Spanish Association Against cancer. Enrique de Alava Casado. (INSTITUTO DE BIOMEDICINA DE SEVILLA). 01/10/2013-01/10/2018. 1.200.000 €.
- 7 PI14/01466, New therapeutic targets in Ewing sarcoma: a study on the microenvironment Instituto de Salud Carlos III-ISCIII. Enrique de Alava Casado. (INSTITUTO DE BIOMEDICINA DE SEVILLA). 01/01/2015-31/12/2017. 296.752 €.
- 8 RTC-2014-2102-1, RELEVANCE OF ENDOGLIN IN THE PATHOGENESIS OF EWING SARCOMA: DEVELOPMENT OF INNOVATIVE THERAPEUTICS – ENDOWING MINECO. Enrique de Alava Casado. (INSTITUTO DE BIOMEDICINA DE SEVILLA). 01/01/2015-31/12/2017. 402.998 €.
- 9 PI12/03102, PROspective VALidation of Biomarkers in Ewing Sarcoma for personalised translational medicine (PROVABES). Instituto de Salud Carlos III. José Luis Ordóñez García. (INSTITUTO DE BIOMEDICINA DE SEVILLA). 01/01/2013-31/12/2015. 54.329 €.
- 10 PI1100018, Search, validation, and clinical translation of therapeutic targets in Ewing sarcoma INSTITUTO DE SALUD CARLOS III. Enrique de Alava Casado. (INSTITUTO DE BIOMEDICINA DE SEVILLA). 01/01/2012-31/12/2014. 375.375 €.

### C.3. Participation in R&D and Innovation contracts

#### C.4. Patents

- 1 Michele Biscuola; Enrique de Alava Casado. P201531898. DIAGNÓSTICO DEL CÁNCER DE TEJIDOS BLANDOS Spain. 22/12/2015. Servicio Andaluz de Salud.
- 2 Enrique de Alava Casado. METHODS OF PROGNOSTICATING AND TREATING EWING SARCOMA/PNET AND OTHER NEOPLASMS 23/06/2010. FUNDACION DE INVESTIGACION DEL CANCER.
- 3 Enrique de Alava Casado. MÉTODO PARA EL PRONÓSTICO DE TUMORES DEL DESARROLLO Y USO DE INHIBIDORES DE LA METILACIÓN GÉNICA PARA EL TRATAMIENTO DE LOS MISMOS 18/06/2010. FUNDACION DE INVESTIGACION DEL CANCER.
- 4 Enrique de Alava Casado. PROCEDIMIENTO PARA DISEÑAR UNA TERAPIA INDIVIDUAL ANTITUMORAL BASADO EN LA DETECCIÓN DE LOS NIVELES DE PROTEÍNA HSP90, EL USO DE INHIBIDORES DE LA PROTEÍNA HSP90 PARA LA ELABORACIÓN DE COMPOSICIONES FARMACÉUTICAS, LAS COMPOSICIONES ASÍ OBTENIDAS Y SUS APLICACIONES<B><I></I></B> 13/05/2008. Universidad de Salamanca.